Skip to main content

Now Diagnostics Acquires Cellmic Rapid Assay Reader Technology

NEW YORK (360Dx) – Now Diagnostics said today that it has acquired the rapid assay reader product lines and related assets of Cellmic, a mobile diagnostics company.

Financial and other terms of the deal were not disclosed.

Inglewood, California-based Cellmic has developed a series of smartphone-based rapid assay readers with applications in medical, veterinary, food safety, biodefense, and drugs-of-abuse testing, Now Diagnostics said.

Cellmic was founded in 2011 as a spinout from the University of California, Los Angeles Henry Samueli School of Engineering and Applied Science. Its products are CE marked and used around the world.

Now Diagnostics CEO Kevin Clark said in a statement that the strategic acquisition strengthens its presence in the rapid diagnostics and mobile health space. “This acquisition will allow us to integrate Cellmic’s advanced reader technology with our AdexusDx testing platform, which we expect will result in even more accurate results and provide convenience, simplicity, and cost benefits to US and international point-of-care testing and consumer healthcare markets," he said.

Now Diagnostics' AdexusDx product line uses a single drop of blood to test for a variety of common conditions, illnesses, and diseases, and provides results in minutes. The AdexusDx hCG pregnancy test, a lateral-flow assay, is CE marked and has been cleared by the US Food and Drug Administration. It is branded and marketed in Europe under the First to Know trademark.

Cellmic said it will continue to develop and commercialize a strong IP portfolio supporting additional biophotonics and mobile technologies, including lens-free microscopes and ELISA microplate readers.